BioIndiana
Filter News
Found 1,269 articles
-
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy
8/4/2023
Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab .
-
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
7/25/2023
The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.
-
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
7/17/2023
Acumen Pharmaceuticals, Inc. will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD.
-
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
7/10/2023
MBX Biosciences, Inc. today announced the appointment of Steven Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer (CSO).
-
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
7/6/2023
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a BTK inhibitor.
-
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2023 Financial Results
7/5/2023
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Tuesday, August 1, 2023 at 8:30 a.m. ET.
-
The U.S. Equal Employment Opportunity Commission settled with Eli Lilly for $2.4 million after filing a suit in September over the company’s recruitment of younger workers.
-
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
6/26/2023
POINT Biopharma Global Inc. today announced a collaboration on the development of a global 212 Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercialization of 212Pb-labeled radioligands by each company.
-
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
6/26/2023
POINT Biopharma Global Inc. today announced the publication of preclinical data from their pan-cancer, fibroblast activation protein-α (FAP)-targeted program, PNT2004, at the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), taking place June 24-27, 2023, in Chicago, IL.
-
RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications
6/6/2023
RxLightning today announced that it closed a $17.5 million Series A investment to support the company’s growth and further remove barriers to life-saving therapies.
-
Gate Neurosciences to Highlight New Biomarker Data & Host R&D Day at 2023 ASCP Annual Meeting
5/24/2023
Highlighting new biomarker data and research supporting precision development of the “‘stinel” class at the 2023 ASCP Annual Meeting.
-
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
5/15/2023
POINT Biopharma Global Inc. today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
-
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023
5/15/2023
Zimmer Biomet Holdings, Inc. today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2023.
-
Zimmer Biomet Announces First Quarter 2023 Financial Results
5/2/2023
Zimmer Biomet Holdings, Inc. today reported financial results for the quarter ended March 31, 2023.
-
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
4/24/2023
Lantheus Holdings, Inc. and POINT Biopharma Global, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC).
-
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
4/10/2023
MBX Biosciences, Inc. today announced its participation at the virtual Needham 22nd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Monday, April 17, 2023 at 3:00 p.m. ET.
-
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
3/27/2023
POINT Biopharma Global Inc. today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
-
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
3/27/2023
Acumen Pharmaceuticals, Inc. today reported financial results for the full year ended December 31, 2022 and provided a business update.
-
EVŌQ Nano Presents Breakthrough Nanoparticle Research at ACS Spring 2023 Conference
3/27/2023
EVŌQ Nano scientists presented the culmination of 10 years of research and innovation at the American Chemical Society (ACS) Conference March 26, 2023 in Indianapolis, Indiana.
-
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
3/8/2023
Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD) pathology when initiated in individuals with amyloid plaque but no clinical symptoms of the disease, known as the preclinical stage of AD1.